Yuanbiao Tu

The Jiangxi Province Key Laboratory For Diagnosis
Nanchang, 330004, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

A novel AT1R-targeted near-infrared fluorescent probe enables intraoperative visualization and resection in hepatocellular carcinoma.

A novel AT1R-targeted near-infrared fluorescent probe enables intraoperative visualization and resection in hepatocellular carcinoma.

Journal: Bioorganic chemistry

Published: March 10, 2026

STRaM: A genetic framework for improved cell product provenance for research and clinical translations.

STRaM: A genetic framework for improved cell product provenance for research and clinical translations.

Journal: Communications biology

Published: October 16, 2024

Machine Learning, Virtual Screening and Bioactivity Evaluation to Identify AJ-292/12941271 as an Anti-proliferative Agent and Target mTOR Protein.

Machine Learning, Virtual Screening and Bioactivity Evaluation to Identify AJ-292/12941271 as an Anti-proliferative Agent and Target mTOR Protein.

Journal: Current medicinal chemistry

Published: October 08, 2024

ROC-guided virtual screening, molecular dynamics simulation, and bioactivity validation assessment Z195914464 as a 3CL Mpro inhibitor.

ROC-guided virtual screening, molecular dynamics simulation, and bioactivity validation assessment Z195914464 as a 3CL Mpro inhibitor.

Journal: Biophysical chemistry

Published: August 28, 2024

Visualization of nonsmall-cell lung cancer by near-infrared fluorescence imaging with tumor-targeting peptide ABT-510.

Visualization of nonsmall-cell lung cancer by near-infrared fluorescence imaging with tumor-targeting peptide ABT-510.

Journal: Bioorganic chemistry

Published: June 18, 2024

Virtual Screening, Molecular Dynamics Simulation, and Bioactivity Assessment Validate T13074 as a Dual-target EGFR/c-Met Inhibitor.

Virtual Screening, Molecular Dynamics Simulation, and Bioactivity Assessment Validate T13074 as a Dual-target EGFR/c-Met Inhibitor.

Journal: Current medicinal chemistry

Published: March 01, 2024

In silico method and bioactivity evaluation to discover novel antimicrobial agents targeting FtsZ protein: Machine learning, virtual screening and antibacterial mechanism study.

In silico method and bioactivity evaluation to discover novel antimicrobial agents targeting FtsZ protein: Machine learning, virtual screening and antibacterial mechanism study.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: February 07, 2024

Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.

Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.

Journal: Bioorganic chemistry

Published: January 20, 2024

T6496 targeting EGFR mediated by T790M or C797S mutant: machine learning, virtual screening and bioactivity evaluation study.

T6496 targeting EGFR mediated by T790M or C797S mutant: machine learning, virtual screening and bioactivity evaluation study.

Journal: Journal of biomolecular structure & dynamics

Published: January 04, 2024

Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFRT790M/L858R inhibitors for the treatment of non-small cell lung cancer.

Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFRT790M/L858R inhibitors for the treatment of non-small cell lung cancer.

Journal: Archiv der Pharmazie

Published: December 14, 2023

Preclinical evaluation of AGTR1-Targeting molecular probe for colorectal cancer imaging in orthotopic and liver metastasis mouse models.

Preclinical evaluation of AGTR1-Targeting molecular probe for colorectal cancer imaging in orthotopic and liver metastasis mouse models.

Journal: European journal of medicinal chemistry

Published: November 15, 2023

Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R.

Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R.

Journal: BMC chemistry

Published: October 01, 2023

Showing 1-12 of 24

Last Updated: 09/26/2026